Brazilian propolis mitigates impaired glucose and lipid metabolism in experimental periodontitis in mice

Mayuka Nakajima1,2, Kei Arimatsu2, Takayoshi Minagawa2, Yumi Matsuda1,2, Keisuke Sato1,2, Naoki Takahashi1,2, Takako Nakajima3 and Kazuhisa Yamazaki1*

Abstract

Background: Periodontitis has been implicated as a risk factor for metabolic disorders associated with insulin resistance. Recently, we have demonstrated that orally administered Porphyromonas gingivalis, a representative periodontopathic bacterium, induces endotoxemia via reduced gut barrier function coupled with changes in gut microbiota composition, resulting in systemic inflammation and insulin resistance. Propolis, a resinous substance collected by honeybees from leaf buds and cracks in the bark of various plants, can positively affect metabolic disorders in various experimental models. In this study, we thus aimed to clarify the effect of propolis on impaired glucose and lipid metabolism induced by P. gingivalis administration.

Methods: Eight-week-old male C57BL/6 mice were orally administered P. gingivalis strain W83, propolis ethanol extract powder with P. gingivalis, or vehicle. We then analyzed the expression profile of glucose and lipid metabolism-related genes in the liver and adipose tissues. Serum endotoxin levels were also evaluated by a limulus amebocyte lysate test. In addition, we performed histological analysis of the liver and quantified alveolar bone loss by measuring the root surface area on the lower first molar.

Results: Oral administration of P. gingivalis induced downregulation of genes that improve insulin sensitivity in adipose tissue (C1qtnf9, Irs1, and Sirt1), but upregulation of genes associated with lipid droplet formation and gluconeogenesis (Plin2, Acox, and G6pc). However, concomitant administration of propolis abrogated these adverse effects of P. gingivalis. Consistent with gene expression, histological analysis showed that administered propolis suppressed hepatic steatosis induced by P. gingivalis. Furthermore, propolis inhibited the elevation of serum endotoxin levels induced by P. gingivalis administration. Contrary to the systemic effects, propolis had no beneficial effect on alveolar bone loss.

Conclusion: These results suggest that administration of propolis may be effective in suppressing periodontopathic bacteria-induced metabolic changes that increase the risk of various systemic diseases.

Keywords: Periodontitis, Propolis, Porphyromonas gingivalis, Liver, Adipose tissue, Endotoxemia

* Correspondence: kaz@dent.niigata-u.ac.jp
1Research Unit for Oral-Systemic Connection, Laboratory of Periodontology and Immunology, Division of Oral Science for Health Promotion, Niigata University Graduate School of Medical and Dental Sciences, 5274 Gakkocho 2-ban-cho, Chuo-ku, Niigata 951-8514, Japan
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Periodontal diseases are mainly chronic infectious diseases resulting from responses to a complex dental plaque microbiome containing various periodontopathic bacteria species. Epidemiological studies suggest that periodontitis is a risk factor for various systemic diseases, such as type 2 diabetes [1, 2], atherosclerotic vascular diseases [3, 4], and non-alcoholic fatty liver disease [5]. Among the various periodontopathic bacteria, considerable research has been focused on the role of Porphyromonas gingivalis as a possible mechanism linking periodontal and other human diseases, due to its unique pathogenicity [6] and its association with various diseases. Although the possible significance of common susceptibility cannot be discounted, there are several hypothetical causal mechanisms linking periodontal disease and systemic diseases. First, bacteria from dental plaque invade gingival tissue through ulcerated sulcular epithelial linings of periodontal pockets and then disseminate into systemic circulation. Second, various proinflammatory cytokines produced in inflamed periodontal tissue, which can also enter systemic circulation, are delivered to various tissues and organs and thereby induce an inflammatory response [7].

Interestingly, links between the diseases related to periodontitis and dysbiosis of the gut microbiota are becoming more evident [8, 9]. Recently, we revealed that oral administration of P. gingivalis altered gut microbiota and elicited endotoxemia, thereby inducing systemic inflammation and insulin resistance [10, 11].

Propolis is a plant product collected by honeybees as a resinous mixture from various plants that is mixed with beeswax and other bee secretions. Although the chemical composition of propolis depends on its location of origin, it basically contains beneficial substances, such as phenolic acids, flavonoids, and vitamins [12, 13]. However, the details of the main ingredients have not yet been disclosed.

Propolis has been used as a folk medicine since ancient times due to its anti-inflammatory [14, 15], antimicrobial [16, 17], anti-oxidant [12], and anti-tumour properties [18, 19]. In addition, previous studies have shown the beneficial effect of propolis on diabetes mellitus. Fuliang et al. revealed that administering propolis improved blood glucose levels and modulates glucose and blood lipid metabolism in experimental rat models of diabetes [20]. Kitamura et al. demonstrated that the propolis extract restored glucose intolerance and insulin resistance, as well as blood glucose and plasma cholesterol levels using ob/ob mice [21]. Furthermore, because of its effectiveness on enterobacteria [22], propolis is expected to replace probiotics as a novel regulator of gut microbiota.

In the present study, we evaluated whether systemic inflammation and insulin resistance induced by periodontopathic bacteria through intestinal reactions could be suppressed by administering propolis.

Methods

Mice

Eight-week-old male C57BL/6 mice were obtained from Japan SLC, Inc. (Shizuoka, Japan). The mice were acclimatized under specific pathogen-free conditions and fed regular chow and sterile water until the commencement of infection at nine weeks of age.

Bacterial cultures

P. gingivalis (strain W83) was cultured in modified Gifu anaerobic medium (GAM) broth (Nissui, Tokyo, Japan) in an anaerobic jar (Becton Dickinson Microbiology System, Cockeysville, MD, USA) in the presence of an AnaeroPack™ (Mitsubishi Gas Chemical Co. Inc., Tokyo, Japan) for 48 h at 37 °C. Bacterial suspensions were prepared in phosphate-buffered saline (PBS) without Mg²⁺/Ca²⁺ using established growth curves and spectrophotometric analysis. The number of colony-forming units (CFUs) was standardized by measuring optical density at 600 nm.

Oral administration

The murine experimental periodontitis model was developed according to Baker et al. with slight modifications [23]. In the present study, mice did not receive antibiotic pretreatment before P. gingivalis administration since systemic antimicrobial treatment affects the gut microbiota composition and alters metabolism [24]. In addition, we have observed P. gingivalis-induced alveolar bone resorption without antibiotic pretreatment [25]. A total of 10⁹ CFUs of live P. gingivalis suspended in 100 μL PBS with 2 % carboxymethyl cellulose (Sigma-Aldrich, St. Louis, MO, USA) was given to each mouse via a feeding needle three times a week for 5 weeks. The number of administered bacteria was determined based on the number of P. gingivalis contained in saliva of patients with severe periodontitis [26] and adjusted for body weight. The control group was sham-administered 100 μL PBS with 2 % carboxymethyl cellulose without P. gingivalis. In the propolis group, powdered ethanol extracts of propolis mixed with 2 % carboxymethyl cellulose (200 mg/kg weight) were administered every day during the experimental period in addition to P. gingivalis administration three times a week for 5 weeks. The propolis ethanol extract, including 55 % propolis extract as solid content, standardized to contain minimum 8.0 % artepillin C, was obtained from Yamada Bee Company, Inc. (Okayama, Japan).
During the experimental period, all mice were allowed to eat and drink *ad libitum*. One day after the final treatment, mice were euthanized with CO₂ and their tissues were collected.

**Analysis of gene expression in the liver and adipose tissues**

Total RNA from the liver and adipose tissues were extracted using TRI Reagent® (Molecular Research Center, Inc., Cincinnati, OH, USA). cDNA was synthesized with Transcriptor Universal cDNA Master (Roche Molecular Systems, Inc., Branchburg, NJ, USA). Primers and probes specific for real-time PCR were purchased from Life Technologies Corporation. Reactions were carried out in a final volume of 25 μL in a LightCycler® 96 System (Roche) using TaqMan Gene Expression Assays (Life Technologies Corporation) containing 900 nM each of the forward and reverse primers and a 250 nM probe. The reactions consisted of a 10-min incubation at 95 °C, followed by 45 cycles of a 2-step amplification procedure, consisting of annealing/extension at 60 °C for 1 min and denaturation for 15 s at 95 °C. LightCycler® 96 software (Roche) was used to analyze the standards and carry out the quantification. The relative quantity of each mRNA was normalized to the relative quantity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA.

**Quantification of alveolar bone loss**

The amount of bone loss was assessed from images obtained using a stereomicroscope fitted with a video image marker measurement system (DP2-BSW; Olympus, Tokyo, Japan). We determined the area surrounded by the margin of the submaxillary alveolar bone crest and the cement-enamel junction on the lingual side of the first molar. We measured alveolar bone loss in the mice in a blind manner.

**Endotoxin assay**

Endotoxin levels were determined in sera collected at the end of the experimental period using a Limulus amebocyte lysate test (QCL-1000TM, BioWhittaker, Walkersville, MD, USA) according to the manufacturer’s instructions. Serum samples were diluted 1-to-4 for the assay. Optical densities were measured using an ELISA plate reader (Model 680, Bio-Rad Laboratories, Hercules, CA, USA) at 405 nm.

**Histological analysis of the liver tissue**

The liver tissues of three mice from each group were fixed in 10 % formalin. Briefly, samples were embedded in paraffin, sectioned, and stained with hematoxylin and eosin.

**Statistical analysis**

Prior to beginning the present study, the sample size calculation was performed based on the data from our previous study. With an alpha error of 0.05 and a statistical power of 0.8, the sample size was calculated to require more than seven animals in each group. This was verified by post-hoc analyses. The data were tested for normality using the Kolmogorov-Smirnov test. Because some, but not all, data sets showed a parametric distribution even in a particular gene expression among different treatment groups, all data were assessed by the Kruskal-Wallis test with a post-hoc Dunn’s multiple comparison test using GraphPad Prism® (GraphPad Software, Inc., La Jolla, CA). A probability value of *p* < 0.05 was considered statistically significant.

**Results**

**Effect of *P. gingivalis* administration and/or propolis on the body weight**

After treatment with *P. gingivalis* and propolis, there were no differences among the sham-administered, *P. gingivalis*-administered, or *P. gingivalis* and propolis-administered groups in body weight (Fig. 1) or food intake.

**Fig. 1** Effect of oral administration of *P. gingivalis* or *P. gingivalis* and propolis on body weight. Body weight changes during experimental period in Sham-administered mice (*N* = 7), *P. gingivalis*-administered mice (*N* = 7), and *P. gingivalis* and propolis-administered mice (*N* = 8). All data are mean ± SD. (*p* < 0.05, Kruskal-Wallis test with post-hoc Dunn’s multiple comparison test)
Effect of propolis on the altered gene expression in the liver by *P. gingivalis* administration

Oral administration of *P. gingivalis* significantly increased gene expression of *Plin2* and *Acox*, both of which are associated with lipid metabolism in the liver, while these gene expressions were markedly reduced in the propolis-administered mice (Fig. 2a). Furthermore, administration of propolis suppressed *G6pc* expression, which positively regulates gluconeogenesis, compared to mice administered *P. gingivalis* alone. Conversely, there was no significant change in the expression of the insulin signaling gene *Irs1* among the three groups (Fig. 2b). Although gene expression of the proinflammatory cytokines IL-6 and TNF-α tended to be elevated from the administered *P. gingivalis*, administration of propolis had no effect on the expression of these genes (Fig. 2c).

Administering propolis led to decreased *Plin2* and *Acox* expression, which were associated with the mitigation of hepatic steatosis induced by *P. gingivalis* administration (Fig. 3).

Effect of propolis on the altered gene expression in the adipose tissue by *P. gingivalis* administration

*Il6*, *Tnf*, *C1qtnf9*, and *Adipoq* are known as adipokines that are expressed in adipocytes to modulate glucose and lipid metabolism. The gene expression of the proinflammatory cytokines IL-6 and TNF-α, which suppress insulin signals, tended to be higher in the *P. gingivalis*-administered mice. Conversely, *C1qtnf9*, a gene that improves insulin sensitivity, was more frequently downregulated in the *P. gingivalis*-administered mice. Administration of propolis ameliorated these changes to gene expression induced by *P. gingivalis* administration.

![Fig. 2](image-url) 

**Fig. 2** Effect of oral administration of *P. gingivalis* or propolis on gene expression in the liver. Expression of genes related to lipid metabolism (A), glucose metabolism (B), and inflammation (C). Sham-administered mice (*N* = 7), *P. gingivalis*-administered mice (*N* = 7), Propolis-administered mice (*N* = 8). The relative mRNA expressions of the genes of interest were normalized to the relative quantity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. All data are means ± SD. (*p* < 0.05, Kruskal-Wallis test with post-hoc Dunn’s multiple comparison test)
Furthermore, the genes that improve insulin sensitivity, *Irs1* and *Sirt1*, were downregulated in *P. gingivalis*-administered mice. However, propolis administration reversed the effect of *P. gingivalis* administration on the expression of these genes. In addition, administration of propolis suppressed the *P. gingivalis*-induced increased expression of *Angptl4*, a gene that is supposed to increase insulin resistance (Fig. 4b).

**Effect of propolis on the serum endotoxin levels in *P. gingivalis*-administered mice**

Oral administration of *P. gingivalis* increased serum endotoxin levels, but was not statistically significant. Administration of propolis not only repressed this increase, but also further lowered serum endotoxin levels below those of untreated mice (Fig. 5).

**Effect of propolis on the alveolar bone resorption in *P. gingivalis*-administered mice**

As with the previous studies, oral administration of *P. gingivalis* induced significant alveolar bone resorption. In spite of the beneficial systemic effect of administering propolis, no effect was observed on the *P. gingivalis*-induced alveolar bone resorption (Fig. 6).
Discussion

Periodontal disease is a chronic inflammatory disease likely resulting from dysbiosis of the oral microbiota. Epidemiological studies indicate its association with an increased risk of various diseases, such as diabetes [1, 2], atherosclerotic vascular diseases [3, 4], and rheumatoid arthritis [5]. The underlying mechanisms linking periodontal disease and these diseases have been considered to be endotoxemia and proinflammatory cytokines derived from gingival lesions [7]. We have shown that repeated oral inoculation of \textit{P. gingivalis} induced elevation of serum inflammatory markers (serum amyloid A and IL-6) in mice [27]. However, in this mouse model, administered \textit{P. gingivalis} was not detected in the blood or insulin target tissues and there was little inflammation in the gingival tissues, suggesting that conventional mechanisms for the relationship between periodontitis and systemic diseases may not be applicable, at least in this mouse model. Recently, we have also demonstrated altered gut bacterial composition by repeated oral administration of \textit{P. gingivalis} as a novel underlying mechanism [10, 11]. Since the gut microbial changes are associated with decreased gut barrier function, as evidenced by reduced expression of the tight junction protein gene (Tjp1) and elevated endotoxin levels in the systemic circulation in our previous studies [10, 11], inflammation of adipose and liver tissue seen in the present study was expected to be from bacteria influx and/or bacterial products into these tissues.

In the present study, we have demonstrated that oral administration of \textit{P. gingivalis} altered gene expression associated with tissue-specific pathological changes relating to metabolic syndromes. In the liver, the expression of \textit{Plin2} and \textit{Acox1} was significantly upregulated. \textit{Plin2} is reported to be strongly associated with lipid droplet formation in the liver [28] and \textit{Acox1} is involved in fatty acid oxidation [29]. Both genes play important roles in non-alcoholic fatty liver diseases. \textit{P. gingivalis} administration also seemed to affect glucose metabolism by increasing the expression of \textit{G6pc}. \textit{G6pc} positively regulates gluconeogenesis and can increase blood glucose levels [30].

Adipose tissue plays an important role in mediating insulin sensitivity through various molecules, including adipocytokines. \textit{C1qtnf9} encoding C1q/TNF-related protein (CTRP)9 is a novel and highly conserved paralog of adiponectin and has salutary effects on glucose metabolism and vascular function [31, 32]. \textit{Irs1} [33] and \textit{Sirt1} contribute to improving insulin sensitivity. SIRT1 not only stimulates a glucose-dependent insulin secretion from pancreatic beta cells, but also directly stimulates insulin signaling pathways in insulin-sensitive organs [34]. \textit{Tnf} and \textit{Il6} are further adipocytokines with strong, natural proinflammatory traits that negatively impact insulin signaling. \textit{Angptl4} can also be involved in insulin resistance [35]. Taken together, oral administration of \textit{P. gingivalis} has harmful effects on insulin sensitivity.

Administration of propolis during the experimental period seemed to show no serious adverse effects, as indicated by no change in body weight among the groups. In support of previous studies [21, 36], administering propolis alleviated the detrimental effects on glucose and lipid metabolism induced by oral administration of \textit{P. gingivalis}. Although we have not analyzed the detailed mechanisms by which propolis suppress these harmful effects, it is possible that administration of propolis could affect gut barrier function, either by alteration of gut microbiota composition or direct elevation of gut barrier function. In support of this idea, our previous studies clearly demonstrate that oral administration of \textit{P. gingivalis} changes gut microbiota composition, inducing sustained endotoxemia and systemic inflammation [10, 11]. Another previous work shows high-fat diet-induced obesity influences gut microbiota and induces metabolic endotoxemia [37]. This endotoxemia is considered to be a result of reduced gut barrier function.
In the present study, we also observed that administering *P. gingivalis* tended to increase serum endotoxin levels, while administering propolis completely abrogated the effect of *P. gingivalis*. Although administering propolis had no effect on alveolar bone resorption induced by *P. gingivalis* indicating no local effects on periodontal tissue, low levels of endotoxin activity in the propolis-administered mice could be mediated by anti-microbial effect on *P. gingivalis*. In this regard, several studies have demonstrated a significant antimicrobial effect of propolis on periodontopathic bacteria such as *P. gingivalis* [38–41] and an inhibitory effect on alveolar bone resorption in ligature-induced periodontitis in rats [42, 43]. However, our study demonstrated no suppressive effect of propolis on alveolar bone resorption. The difference between our study and the study by Toker et al. [43] could be due at least in part to the different methods for inducing experimental periodontitis. Alternatively, propolis administration may have induced changes in gut microbiota composition or strengthened the gut barrier function. One previous study showed that propolis up-regulated tight junction proteins in Caco-3 cells and that *in vivo* administration of propolis increased colonic epithelial ZO-1 expression [44]. Furthermore, it has been demonstrated that a gut metabolite of linoleic acid ameliorates inflammation-induced intestinal epithelial barrier impairments, suggesting that gut microbiota composition is crucial for the maintenance of gut barrier function [45]. Thus, it is reasonable to consider the beneficial effects of propolis on gut microbiota.

**Conclusion**

Although further studies are needed to clarify the underlying mechanism by which propolis suppresses *P. gingivalis*-induced metabolic disturbance, our results suggest that administration of propolis may be effective in suppressing periodontopathic bacteria-induced metabolic changes that increase the risk of various systemic diseases.

**Acknowledgements**

The authors thank Yamada Apiculture Center, Inc., Okayama, Japan, for the generous gift of the Brazilian propolis ethanolic extracts.

**Funding**

This work was supported by YAMADA BEE FARM (Grant Number 0170, Okayama, Japan) and JSPS KAKENHI (Grant Numbers 25463216, 25670882, 15H02578 and 15 K15763, 16H05554).
Availability of data and materials
All data analyzed during this study are included in this published article.

Authors’ contributions
MN researched data and wrote the manuscript. KA, TM, YM, KS researched data. NT and TN contributed to discussion. KY planned the study and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests
K. Yamazaki received a grant from Yamada BEE FARM (Okayama, Japan), but did not have any other role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. None of other authors have any competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
All experiments were performed in accordance with the Regulations and Guidelines on Scientific and Ethical Care and Use of Laboratory Animals of the Science Council of Japan, enforced on June 1, 2006, and approved by the Institutional Animal Care and Use Committee at Niigata University (permit number 61-4).

Author details
1 Research Unit for Oral-Systemic Connection, Laboratory of Periodontology and Immunology, Division of Oral Science for Health Promotion, Niigata University Graduate School of Medical and Dental Sciences, 5274 Gakkocho, Chuo-ku, Niigata 951-8514, Japan. 2 Division of Periodontology, Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 3 Division of Dental Educational Research Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Received: 2 March 2016 Accepted: 19 August 2016
Published online: 30 August 2016

References
1. Chavarry NG, Vettore MV, Sansone C, Sheiham A. The relationship between diabetes mellitus and destructive periodontal disease: a meta-analysis. Oral Health Prev Dent. 2009;7(2):107–27.
2. Salvi GE, Carollo-Bittel B, Lang NP. Effects of diabetes mellitus on periodontal and peri-implant conditions: update on associations and risks. J Clin Periodontol. 2008;35(8 Suppl):398–409.
3. Bahaeer AA, Singh S, Saha S, Mohjar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am Heart J. 2007;154(5):830–7.
4. Humphrey LL, Fu R, Buckley D, Freeman M, Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med. 2008;23(12):2079–86.
5. Yoneda M, Naka S, Nakano K, Wada K, Endo H, Kawatri H, Imao K, Nomura R, Hokamura K, Oho M, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Microbiol. 2012;12:16.
6. Bostanci N, Belibasakis GN. Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen. FEMS Microbiol Lett. 2012;333(1):1–9.
7. Cullinan MP, Seymour GJ. Periodontal disease and systemic illness: will the evidence ever be clear? Periodontol 2000. 2013;62(1):271–86.
8. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260–70.
9. Fukuda S, Oho H. Gut microbiome and metabolic diseases. Semin Immunopathol. 2014;36(1):103–14.
10. Arimatsu K, Yamada H, Miyazawa H, Minagawa T, Nakajima M, Ryder ML, Gotch K, Mutooka D, Nakamura S, Iida T, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014;4:4828.
11. Nakajima M, Arimatsu K, Kato T, Matsuda Y, Minagawa T, Takahashi N, Oho H, Yamazaki K. Oral Administration of P. gingivalis Induces Dysbiosis of Gut Microbiota and Impaired Barrier Function Leading to Dissemination of Enterobacteria to the Liver. PLoS One. 2015;10(7):e0134234.
12. Kurek-Gorecka A, Rzepecka-Stojko A, Gorecki M, Stojko J, Sosada M, Swierczek-Zielska G. Structure and antioxidant activity of polyphenols derived from propolis. Molecules. 2013;19(1):78–101.
13. Marcucci MC, Fereres F, Garcia-Viguera C, Bankova VS, De Castro SL, Dantas AP, Valente PH, Paulino N. Phenolic compounds from Brazilian propolis with pharmacological activities. J Ethnopharmacol. 2001;74(2):105–12.
14. Machado JL, Ansucuo AK, da Silva MC, Dos Reis AS, Costa GC, Anruda Dde S, Boca RA, Vaz MM, Paes AM, Guerra RN, et al. Brazilian green propolis: anti-inflammatory property by an immunomodulatory activity. Evid Based Complement Alternat Med. 2012;2012:157652.
15. Borrelli F, Mafla P, Pinto L, Ianaro A, Russo A, Capasso F, Ialenti A. Phytochemical compounds involved in the anti-inflammatory effect of propolis extract. Fitoterapia. 2002;73 Suppl 1:53–63.
16. Woltyczka RD, Kepa M, Idzik D, Kubiana R, Kabala-Dzik A, Dziedzic A, Wasik TJ. In Vitro Antimicrobial Activity of Ethanol Extract of Polish Propolis against Biofilm Forming Staphylococcus epidermidis. Evid Based Complement Alternat Med. 2013;2013:590703.
17. Tan-No K, Nakajima T, Shoji T, Nakagawasaki O, Nikiina F, Ishikawa M, Endo Y, Sato T, Satch S, Tamado T. Anti-inflammatory effect of propolis through inhibition of nitric oxide production on carrageenin-induced mouse paw edema. Biol Pharm Bull. 2006;29(1):96–9.
18. Padmavathi R, Senthilnathan P, Sakhitekaran D. Therapeutic effect of propolis and paclitaxel on hepatic phase I and II enzymes and marker enzymes in dimethylbenz(a)anthracene-induced breast cancer in female rats. Comp Biochem Physiol C Toxicol Pharmacol. 2006;143(3):349–54.
19. Shimizu K, Das SK, Hashimoto T, Sowa Y, Yoshida T, Sakai T, Matsuya M, Kanazawa K, Arteplin C. In Brazilian propolis induces GO(0/1) arrest via stimulation of Cip1/p21 expression in human colon cancer cells. Mol Carcinog. 2005;44(4):293–9.
20. Fuliang HU, Hebpurn HR, Xuan H, Chen H, Daya S, Radloff SE. Effects of propolis on blood glucose, blood lipid and free radicals in rats with diabetes mellitus. Pharmcol Res. 2005;51(12):147–52.
21. Kitamura H, Naoe Y, Kimura S, Miyamoto T, Okamoto S, Toda C, Shimamoto Y, Iwana T, Miyoshi Y. Beneficial effects of Brazilian propolis on type 2 diabetes in ob/ob mice. Possible involvement of immune cells in mesenteric adipose tissue. Adipocyte. 2013;2(4):227–36.
22. Li J, Kim IH. Effects of Saccharomyces cerevisiae cell wall extract and propolis ethanol extract supplementation on growth performance, digestibility, blood profile, fecal microbiota and fecal noxious gas emissions in growing pigs. Anim Sci J. 2014;85(6):698–705.
23. Baker PJ, Evans RT, Roopenian DC. Oral infection with Porphyromonas gingivalis and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. Archs oral Biol. 1994;39(12):1035–40.
24. Cavalo BM, Guadagnini D, Tsukumo DM, Schenka AA, Latuf-Filho P, Vassallo J, Dias JC, Kubota LT, Carvalheira JB, Saad MJ. Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia. 2012;55(10):2823–34.
25. Yamada H, Nakajima T, Dornon H, Honda T, Yamazaki K. Endoplasmic reticulum stress response and bone loss in experimental periodontitis in mice. J Periodontol Res. 2015;50(4):500–8.
26. von Troil-Linden B, Torkko H, Alatusuu S, Jouinsm-Somer H, Askainen S. Salivary levels of suspected periodontal pathogens in relation to periodontal status and treatment. J Dent Res. 1995;74(11):1379–85.
27. Maekawa T, Takahashi T, Tabelka K, Aoki Y, Miyashita H, Miyachi S, Miyazawa H, Nakajima T, Yamazaki K. Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile. PLoS One. 2011;6(5):e20240.
28. Okumawti C, Sosada M, Askainen S. Environmental influences of gut microbiota. Microbiol Mol Biol Rev. 2013;77(2):425–51.
29. Kambara T, Ohashi K, Shibata R, Ogura Y, Maruyama S, Enomoto T, Uemura Y, Iwanaga T, Miyoshi I. Beneficial effects of Brazilian propolis on type 2 diabetes in ob/ob mice. Possible involvement of immune cells in mesenteric adipose tissue. Adipocyte. 2013;2(4):227–36.
30. Li J, Kim IH. Effects of Saccharomyces cerevisiae cell wall extract and propolis ethanol extract supplementation on growth performance, digestibility, blood profile, fecal microbiota and fecal noxious gas emissions in growing pigs. Anim Sci J. 2014;85(6):698–705.
31. von Troil-Linden B, Torkko H, Alatusuu S, Jouinsm-Somer H, Askainen S. Salivary levels of suspected periodontal pathogens in relation to periodontal status and treatment. J Dent Res. 1995;74(11):1379–85.
32. Maekawa T, Takahashi T, Tabelka K, Aoki Y, Miyashita H, Miyachi S, Miyazawa H, Nakajima T, Yamazaki K. Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile. PLoS One. 2011;6(5):e20240.
33. Okumawti C, Sosada M, Askainen S. Environmental influences of gut microbiota. Microbiol Mol Biol Rev. 2013;77(2):425–51.
32. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Ge G, Spooner E, Hug C, Gimeno R, Lodish HF. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J. 2009;23(1):241–58.
33. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012;55(10):2565–82.
34. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol. 2009;5(7):367–73.
35. Okie Y, Akao M, Kubiota Y, Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med. 2005;11(10):473–9.
36. Ichi I, Hori H, Takashima Y, Adachi N, Kataoka R, Okihara K, Hashimoto K, Kojo S. The beneficial effect of propolis on fat accumulation and lipid metabolism in rats fed a high-fat diet. J Food Sci. 2009;74(5):H127–31.
37. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Debenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81.
38. Agarwal G, Vemanaradhya GG, Mehta DS. Evaluation of chemical composition and efficacy of Chinese propolis extract on Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans: An in vitro study. Contemp Clin Dent. 2012;3(3):256–61.
39. Koo H, Gomes BP, Rosalen PL, Ambrosano GM, Park YK, Cury JA. In vitro antimicrobial activity of propolis and Arnica montana against oral pathogens. Archs oral Biol. 2000;45(2):141–8.
40. Koru O, Toksoy F, Ackel CH, Tuncu YM, Baysal M, Uskudar Gucel A, Akca E, Ozkok Tuyulu A, Sorkun K, Tanyukel M, et al. In vitro antimicrobial activity of propolis samples from different geographical origins against certain oral pathogens. Anaerobe. 2007;13(3-4):140–5.
41. Santos FA, Bastos EM, Rodrigues PH, de Uzeda M, de Carvalho MA, Farias Lde M, Moreira ES. Susceptibility of Prevotella intermedia/Prevotella nigrescens (and Porphyromonas gingivalis) to propolis (bee glue) and other antimicrobial agents. Anaerobe. 2002;8(1):19–15.
42. Axal CA, Kesim S, Greenwell H, Kara M, Cetin A, Yakan B. Alveolar bone protective and hypoglycemic effects of systemic propolis treatment in experimental periodontitis and diabetes mellitus. J Med Food. 2015;18(2):195–201.
43. Toker H, Ozan F, Ozer H, Ozdemir H, Eren K, Yeler H. A morphometric and histopathologic evaluation of the effects of propolis on alveolar bone loss in experimental periodontitis in rats. J Periodontol. 2008;79(6):1089–94.
44. Wang K, Jin X, Chen Y, Song Z, Jiang X, Hu F, Conlon MA, Topping DL. Polyphenol-Rich Propolis Extracts Strengthen Intestinal Barrier Function by Activating AMPK and ERK Signaling. Nutrients. 2016;8(5). doi:10.3390/ nu8050272.
45. Miyamoto J, Mizukura T, Park SB, Kishino S, Kimura J, Hirao K, Bergamo P, Rossi M, Suzuki T, Arita M, et al. A gut microbial metabolite of Indole acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem. 2015;290(5):3902–18.